Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City. (12th June 2021)

• Record Type: Journal Article
• Authors: Cowman, Kelsie; Guo, Yi; Pirofski, Liise-anne; Wong, David; Bao, Hongkai; Chen, Victor; Hopkins, Una; Andrews, Erin; Hamel, Joseph; Keller, Marla; Bellin, Eran; Thota, Raja; Davis, Patricia; Rodriguez, Edwin Torres; Suthar, Pooja; Allen, Lauren; Rossi, James; Haviland, Adam; Orner, Erika; Szymczak, Wendy; Shujauddin, Sadahf; McCarthy, James; Binder, Barbara; Pushparaj, Vanitha; Bard, Linda; Pierino, Vincent Frank; Alsina, Leslie; Esses, David; McCaskie, Alicia; Campbell, Caron; Madzura, Tabitha; Wollowitz, Andrew; Basset, Kelly; White, Deborah; Ruiz, Rafael; Sosnowski, Frank; Nori, Priya;
• Is Part Of: Open forum infectious diseases. Volume 8:Number 8(2021)
• Publication Date: 2021-06-12
• Subjects: antimicrobial stewardship -- COVID-19 -- monoclonal antibodies -- SARS-CoV-2 variants; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab313
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City. Graphical Abstract: